Tvardi Therapeutics, Inc. (TVRD) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001346830 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | — | $-6.5M | $-0.69 | Filing |
| Mar 31, 2026 | May 8, 2026 | — | $-6.8M | $-0.73 | Filing |
| Dec 31, 2025 | Mar 31, 2026 | — | $-7.3M | $2.05 | Filing |
| Sep 30, 2025 | Nov 13, 2025 | — | $-5.5M | $-0.59 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | — | $4.2M | $-1.00 | Filing |
| Mar 31, 2025 | May 13, 2025 | $2.6M | $-9.6M | $-3.72 | Filing |
| Dec 31, 2024 | Mar 11, 2025 | $1.5M | $-12.7M | $13.67 | Filing |
| Sep 30, 2024 | Nov 14, 2024 | $2.6M | $-5.5M | $-2.14 | Filing |
What would Tvardi Therapeutics, Inc. have to report for its valuation to change?
At $1.01, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 16.6% a year, to $0.09. On that path the next quarter needs diluted EPS near $-0.69, against $-0.59 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 16.6% | 16.6% |
| EPS needed in final year | $0.09 | $0.09 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. TVRD goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.